Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.
Identifieur interne : 000C38 ( PubMed/Corpus ); précédent : 000C37; suivant : 000C39Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.
Auteurs : Alim Louis Benabid ; Stephan Chabardes ; John Mitrofanis ; Pierre PollakSource :
- The Lancet. Neurology [ 1474-4422 ] ; 2009.
English descriptors
- KwdEn :
- Cohort Studies, Deep Brain Stimulation (adverse effects), Deep Brain Stimulation (contraindications), Electrodes (adverse effects), Humans, Muscle Rigidity (etiology), Muscle Rigidity (therapy), Neurosurgical Procedures (adverse effects), Parkinson Disease (complications), Parkinson Disease (psychology), Parkinson Disease (therapy), Prognosis, Quality of Life, Randomized Controlled Trials as Topic, Speech Disorders (etiology), Speech Disorders (therapy), Subthalamic Nucleus (physiology), Treatment Outcome, Tremor (etiology), Tremor (therapy).
- MESH :
- adverse effects : Deep Brain Stimulation, Electrodes, Neurosurgical Procedures.
- complications : Parkinson Disease.
- contraindications : Deep Brain Stimulation.
- etiology : Muscle Rigidity, Speech Disorders, Tremor.
- physiology : Subthalamic Nucleus.
- psychology : Parkinson Disease.
- therapy : Muscle Rigidity, Parkinson Disease, Speech Disorders, Tremor.
- Cohort Studies, Humans, Prognosis, Quality of Life, Randomized Controlled Trials as Topic, Treatment Outcome.
Abstract
High-frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN-HFS) is the preferred surgical treatment for advanced Parkinson's disease. In the 15 years since its introduction into clinical practice, many studies have reported on its benefits, drawbacks, and insufficiencies. Despite limited evidence-based data, STN-HFS has been shown to be surgically safe, and improvements in dopaminergic drug-sensitive symptoms and reductions in subsequent drug dose and dyskinesias are well documented. However, the procedure is associated with adverse effects, mainly neurocognitive, and with side-effects created by spread of stimulation to surrounding structures, depending on the precise location of electrodes. Quality of life improves substantially, inducing sudden global changes in patients' lives, often requiring societal readaptation. STN-HFS is a powerful method that is currently unchallenged in the management of Parkinson's disease, but its long-term effects must be thoroughly assessed. Further improvements, through basic research and methodological innovations, should make it applicable to earlier stages of the disease and increase its availability to patients in developing countries.
DOI: 10.1016/S1474-4422(08)70291-6
PubMed: 19081516
Links to Exploration step
pubmed:19081516Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.</title><author><name sortKey="Benabid, Alim Louis" sort="Benabid, Alim Louis" uniqKey="Benabid A" first="Alim Louis" last="Benabid">Alim Louis Benabid</name><affiliation><nlm:affiliation>Department of Neurosurgery and Neurology, University of Grenoble, CHU Albert Michallon, Grenoble, France. AlimLouis@aol.com</nlm:affiliation></affiliation></author><author><name sortKey="Chabardes, Stephan" sort="Chabardes, Stephan" uniqKey="Chabardes S" first="Stephan" last="Chabardes">Stephan Chabardes</name></author><author><name sortKey="Mitrofanis, John" sort="Mitrofanis, John" uniqKey="Mitrofanis J" first="John" last="Mitrofanis">John Mitrofanis</name></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:19081516</idno><idno type="pmid">19081516</idno><idno type="doi">10.1016/S1474-4422(08)70291-6</idno><idno type="wicri:Area/PubMed/Corpus">000C38</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.</title><author><name sortKey="Benabid, Alim Louis" sort="Benabid, Alim Louis" uniqKey="Benabid A" first="Alim Louis" last="Benabid">Alim Louis Benabid</name><affiliation><nlm:affiliation>Department of Neurosurgery and Neurology, University of Grenoble, CHU Albert Michallon, Grenoble, France. AlimLouis@aol.com</nlm:affiliation></affiliation></author><author><name sortKey="Chabardes, Stephan" sort="Chabardes, Stephan" uniqKey="Chabardes S" first="Stephan" last="Chabardes">Stephan Chabardes</name></author><author><name sortKey="Mitrofanis, John" sort="Mitrofanis, John" uniqKey="Mitrofanis J" first="John" last="Mitrofanis">John Mitrofanis</name></author><author><name sortKey="Pollak, Pierre" sort="Pollak, Pierre" uniqKey="Pollak P" first="Pierre" last="Pollak">Pierre Pollak</name></author></analytic><series><title level="j">The Lancet. Neurology</title><idno type="ISSN">1474-4422</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cohort Studies</term><term>Deep Brain Stimulation (adverse effects)</term><term>Deep Brain Stimulation (contraindications)</term><term>Electrodes (adverse effects)</term><term>Humans</term><term>Muscle Rigidity (etiology)</term><term>Muscle Rigidity (therapy)</term><term>Neurosurgical Procedures (adverse effects)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (psychology)</term><term>Parkinson Disease (therapy)</term><term>Prognosis</term><term>Quality of Life</term><term>Randomized Controlled Trials as Topic</term><term>Speech Disorders (etiology)</term><term>Speech Disorders (therapy)</term><term>Subthalamic Nucleus (physiology)</term><term>Treatment Outcome</term><term>Tremor (etiology)</term><term>Tremor (therapy)</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Deep Brain Stimulation</term><term>Electrodes</term><term>Neurosurgical Procedures</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="contraindications" xml:lang="en"><term>Deep Brain Stimulation</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Muscle Rigidity</term><term>Speech Disorders</term><term>Tremor</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Subthalamic Nucleus</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Muscle Rigidity</term><term>Parkinson Disease</term><term>Speech Disorders</term><term>Tremor</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cohort Studies</term><term>Humans</term><term>Prognosis</term><term>Quality of Life</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">High-frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN-HFS) is the preferred surgical treatment for advanced Parkinson's disease. In the 15 years since its introduction into clinical practice, many studies have reported on its benefits, drawbacks, and insufficiencies. Despite limited evidence-based data, STN-HFS has been shown to be surgically safe, and improvements in dopaminergic drug-sensitive symptoms and reductions in subsequent drug dose and dyskinesias are well documented. However, the procedure is associated with adverse effects, mainly neurocognitive, and with side-effects created by spread of stimulation to surrounding structures, depending on the precise location of electrodes. Quality of life improves substantially, inducing sudden global changes in patients' lives, often requiring societal readaptation. STN-HFS is a powerful method that is currently unchallenged in the management of Parkinson's disease, but its long-term effects must be thoroughly assessed. Further improvements, through basic research and methodological innovations, should make it applicable to earlier stages of the disease and increase its availability to patients in developing countries.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19081516</PMID><DateCreated><Year>2008</Year><Month>12</Month><Day>16</Day></DateCreated><DateCompleted><Year>2009</Year><Month>02</Month><Day>06</Day></DateCompleted><DateRevised><Year>2014</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1474-4422</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2009</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>67-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(08)70291-6</ELocationID><Abstract><AbstractText>High-frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN-HFS) is the preferred surgical treatment for advanced Parkinson's disease. In the 15 years since its introduction into clinical practice, many studies have reported on its benefits, drawbacks, and insufficiencies. Despite limited evidence-based data, STN-HFS has been shown to be surgically safe, and improvements in dopaminergic drug-sensitive symptoms and reductions in subsequent drug dose and dyskinesias are well documented. However, the procedure is associated with adverse effects, mainly neurocognitive, and with side-effects created by spread of stimulation to surrounding structures, depending on the precise location of electrodes. Quality of life improves substantially, inducing sudden global changes in patients' lives, often requiring societal readaptation. STN-HFS is a powerful method that is currently unchallenged in the management of Parkinson's disease, but its long-term effects must be thoroughly assessed. Further improvements, through basic research and methodological innovations, should make it applicable to earlier stages of the disease and increase its availability to patients in developing countries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benabid</LastName><ForeName>Alim Louis</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurosurgery and Neurology, University of Grenoble, CHU Albert Michallon, Grenoble, France. AlimLouis@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chabardes</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mitrofanis</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pollak</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="Y">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000744" MajorTopicYN="N">contraindications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004566" MajorTopicYN="N">Electrodes</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009127" MajorTopicYN="N">Muscle Rigidity</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019635" MajorTopicYN="N">Neurosurgical Procedures</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013064" MajorTopicYN="N">Speech Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014202" MajorTopicYN="N">Tremor</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>175</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19081516</ArticleId><ArticleId IdType="pii">S1474-4422(08)70291-6</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(08)70291-6</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C38 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000C38 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19081516
|texte= Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19081516" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |